前列腺癌手术过度治疗的趋势
这项回顾性队列研究分析了2010年至2024年间接受前列腺切除术患者的病理分级,发现pGG1前列腺切除术比例在SEER从32.4%降至7.8%,在MUSIC从20.7%降至2.7%,且近期手术的pGG1病例更可能具有术前高风险特征。
要点
- SEER中pGG1前列腺切除术比例从2010年32.4%降至2020年7.8%,MUSIC中从2012年20.7%降至2024年2.7%。
- 校正年龄和种族后,较近期手术与pGG1前列腺切除术可能性降低相关(SEER OR每5年0.41,MUSIC OR每5年0.39)。
- 在pGG1子集中,较近期手术与术前高风险特征存在相关(SEER和MUSIC OR每5年均为1.60)。
核心结论
- 自2010年以来,pGG1前列腺切除术的频率显著下降,且少数进行的pGG1手术更可能具有高风险特征,这反映了诊断路径改善、对低风险病例主动监测方案的依从以及减少不必要手术干预的努力。
研究设计与样本
- 回顾性队列研究,纳入SEER数据库162558例和MUSIC数据库23370例接受前列腺切除术的男性患者,手术时间范围为2010年1月1日至2024年9月1日。
主要发现
- SEER中pGG1前列腺切除术比例从2010年32.4%(5852/18071)降至2020年7.8%(978/12500);MUSIC中从2012年20.7%(83/401)降至2024年2.7%(32/1192)。
- 校正年龄和种族后,较近期手术与pGG1前列腺切除术可能性降低相关:SEER OR每5年0.41(95%CI 0.40-0.42,P<.001),MUSIC OR每5年0.39(95%CI 0.36-0.43,P<.001)。
- 在最终病理为pGG1的子集分析中,较近期手术与术前高风险特征存在相关:SEER OR每5年1.60(95%CI 1.54-1.67,P<.001),MUSIC OR每5年1.60(95%CI 1.34-1.90,P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Overtreatment of prostate cancer is a public health concern that undermines prostate cancer screening efforts. OBJECTIVE: To assess trends in pathologic grade on prostatectomy during the past 2 decades as a surrogate for overtreatment. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study examined the grade of prostate cancer on final pathology reports among patients undergoing prostatectomy between January 1, 2010, and September 1, 2024, in 2 parallel cohorts: Surveillance, Epidemiology, and End Results (SEER), a nationwide cancer registry, and Michigan Urological Surgery Improvement Collaborative (MUSIC), a statewide clinical registry. The presence of higher-risk features among patients who underwent grade group 1 prostatectomy during this period was also assessed. EXPOSURES: The primary exposure of interest was year of radical prostatectomy. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of all prostatectomies that were pathologic grade group 1 (pGG1) on final pathology reports. The secondary outcome was the proportion of pGG1 prostatectomies with a higher-risk preoperative feature, assessed as a binary variable and including at least 1 of the following: more than 50% of biopsy cores positive, prostate-specific antigen of 10 ng/mL or higher, or grade group 2 on biopsy. RESULTS: A total of 162 558 male patients in SEER (median [IQR] age, 63 [57-67] years) and 23 370 in MUSIC (median [IQR] age, 64 [59-69] years) underwent prostatectomy. The proportion of radical prostatectomies resulting in pGG1 on final pathology reports decreased from 32.4% (5852 of 18 071) to 7.8% (978 of 12 500) between 2010 and 2020 in SEER and from 20.7% (83 of 401) to 2.7% (32 of 1192) between 2012 and 2024 in MUSIC. A more recent prostatectomy was associated with a lower likelihood of a pGG1 prostatectomy while controlling for age and race within SEER (odds ratio [OR] per 5 years, 0.41; 95% CI, 0.40-0.42; P < .001) and MUSIC (OR per 5 years, 0.39; 95% CI, 0.36-0.43; P < .001). Within a subset analysis of those prostatectomies that were final pGG1, a more recent prostatectomy was associated with the presence of a higher-risk preoperative feature, including more than 50% of biopsy cores positive, prostate-specific antigen of 10 ng/mL or higher, and grade group 2 on prior biopsy within SEER (OR per 5 years, 1.60; 95% CI, 1.54-1.67; P < .001) and MUSIC (OR per 5 years, 1.60; 95% CI, 1.34-1.90; P < .001). CONCLUSIONS AND RELEVANCE: This cohort study found that since 2010, the frequency of pGG1 prostatectomies markedly decreased, and those few that were performed were more likely to have a higher-risk feature. This reduction in the proportion of prostatectomies that are pGG1 likely reflects improved diagnostic pathways, adherence to active surveillance protocols for low-risk cases, and ongoing efforts at both the state and national levels to minimize unnecessary surgical interventions in patients diagnosed with clinically insignificant prostate cancer.
引用
- Monda SM, Demus T, Jaime-Casas S, et al. Trends in Surgical Overtreatment of Prostate Cancer. JAMA Oncol. 2025. PMID: 40292607. doi:10.1001/jamaoncol.2025.0963
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。